Neurocrine Biosciences (NASDAQ: NBIX) net income
Neurocrine Biosciences reported a net profit of $478.6m for fiscal 2025, 40.2% more than in fiscal 2024 ($341.3m). Its net margin was 16.7%. Earnings per share were $4.81.
Neurocrine Biosciences has grown its net income for 4 years in a row, and fiscal 2025 is the highest of its 10 fiscal years on record. The biggest drop was in fiscal 2021, −78.0%. It reported a loss in 2 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | $478.6m | +40.2% | 16.7% | $4.81 |
| 2024 | $341.3m | +36.7% | 14.5% | $3.40 |
| 2023 | $249.7m | +61.6% | 13.2% | $2.56 |
| 2022 | $154.5m | +72.4% | 10.4% | $1.61 |
| 2021 | $89.6m | −78.0% | 7.9% | $0.95 |
| 2020 | $407.3m | +1,000.8% | 38.9% | $4.38 |
| 2019 | $37.0m | +75.4% | 4.7% | $0.40 |
| 2018 | $21.1m | — | 4.7% | $0.23 |
| 2017 | −$142.5m | — | −88.2% | −$1.62 |
| 2016 | −$141.1m | — | −940.6% | −$1.63 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Neurocrine Biosciences net income compared with its sector
By net income for its latest fiscal year, Neurocrine Biosciences ranks 60th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Neurocrine Biosciences, 16.7%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 58th | Community Health Systems | $509.0m | 4.1% |
| 59th | West Pharmaceutical Services | $493.7m | 16.1% |
| 60th | Neurocrine Biosciences | $478.6m | 16.7% |
| 61st | Molina Healthcare | $472.0m | 1.0% |
| 62nd | Medpace | $451.1m | 17.8% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Neurocrine Biosciences
- How much did Neurocrine Biosciences earn in fiscal 2025?
- Neurocrine Biosciences reported a net profit of $478.6m for fiscal 2025. In fiscal 2024 it reported a net profit of $341.3m.
- What are the earnings per share of Neurocrine Biosciences?
- They were $4.81 in fiscal 2025, compared with $3.40 in fiscal 2024.
- What is the net margin of Neurocrine Biosciences?
- In fiscal 2025 its net profit was 16.7% of its revenue.
- What was the most profitable year for Neurocrine Biosciences?
- Of its last 10 fiscal years, fiscal 2025, with $478.6m.
- Where does Neurocrine Biosciences rank in its sector by net income?
- It ranks 60th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Neurocrine Biosciences come from?
- From the annual report (Form 10-K) that Neurocrine Biosciences files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Neurocrine Biosciences files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Neurocrine Biosciences: the Neurocrine Biosciences page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.